Iconovo (ICO) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
1 Oct, 2026Rights issue and investor presentation
Announced a rights issue of approximately 36.6 MSEK, approved by the board and EGM, with subscription from 16 May to 2 June 2025.
Investor presentation scheduled for 21 May 2025, hosted digitally by the CEO to discuss the business and rights issue.
Information document for the rights issue registered with the Swedish Financial Supervisory Authority and available online.
Financial and legal advisors engaged for the rights issue include DNB Carnegie SME and Setterwalls Advokatbyrå AB.
Regulatory and legal considerations
The information document is not a prospectus and has not been approved by any regulatory authority.
Securities will not be offered or sold in the United States or other restricted jurisdictions.
In the UK, the offer is directed only at qualified investors and relevant persons.
Forward-looking statements and risk factors
Contains forward-looking statements about future results, strategies, and market opportunities.
Actual outcomes may differ materially due to risks and uncertainties; no guarantee on assumptions.
No obligation to update forward-looking statements unless required by law or market rules.
Latest events from Iconovo
- Near-term ICOres and ICOpre deals are pivotal to commercialization and funding.ICO
Q3 2026 - Improved financials and strategic partnerships set the stage for growth, pending key licensing deals.ICO
Q2 2026 - Net sales grew 45% and losses narrowed, with financing secured and strategic partnerships advancing.ICO
Q1 2026 - Declining sales and losses prompt capital raise and strategic shift toward partnerships and GLP-1 projects.ICO
Q4 2025 - Strategic refocus and cost cuts in Q3 2025 position for growth in inhalers and semaglutide.ICO
Q3 2025 - Restructuring and capital raise position the company for commercialization despite lower sales.ICO
Q2 2025 - No Q3 revenue; key inhaler projects advanced, rights issue to fund next phase.ICO
Q3 2024 - Strategic progress in inhaler IP, licensing, and obesity drug reformulation, with improved losses.ICO
Q2 2024 - Iconovo pivots to commercialization, secures funding, and advances inhalable drug partnerships.ICO
Q1 2025